These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34958099)

  • 1. Expected Rates of Select Adverse Events After Immunization for Coronavirus Disease 2019 Vaccine Safety Monitoring.
    Abara WE; Gee J; Delorey M; Tun Y; Mu Y; Shay DK; Shimabukuro T
    J Infect Dis; 2022 May; 225(9):1569-1574. PubMed ID: 34958099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A
    Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
    Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
    Pillsbury A; Phillips A; Deng L; Quinn H; Macartney K; Gidding H
    Vaccine; 2023 May; 41(22):3422-3428. PubMed ID: 37088604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Nasreen S; Calzavara A; Buchan SA; Thampi N; Johnson C; Wilson SE; Kwong JC;
    Vaccine; 2022 May; 40(24):3305-3312. PubMed ID: 35527057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?
    Oo WM; Giri P; de Souza A
    J Neuroimmunol; 2021 Nov; 360():577719. PubMed ID: 34560365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post COVID-19 vaccination Guillain-Barre syndrome: three cases.
    Tabatabaee S; Rezania F; Alwedaie SMJ; Malekdar E; Badi Z; Tabatabaei SM; Mirzaasgari Z
    Hum Vaccin Immunother; 2022 Nov; 18(5):2045153. PubMed ID: 35240922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2.
    Leung C
    Hum Vaccin Immunother; 2021 Sep; 17(9):2957-2958. PubMed ID: 34032555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study.
    Jeong HS; Chun BC
    PLoS One; 2024; 19(2):e0297902. PubMed ID: 38381729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
    Moll K; Lufkin B; Fingar KR; Ke Zhou C; Tworkoski E; Shi C; Hobbi S; Hu M; Sheng M; McCarty J; Shangguan S; Burrell T; Chillarige Y; Beers J; Saunders-Hastings P; Muthuri S; Edwards K; Black S; Kelman J; Reich C; Amend KL; Djibo DA; Beachler D; Ogilvie RP; Secora A; McMahill-Walraven CN; Seeger JD; Lloyd P; Thompson D; Dimova R; MaCurdy T; Obidi J; Anderson S; Forshee R; Wong HL; Shoaibi A
    Vaccine; 2023 Jan; 41(2):333-353. PubMed ID: 36404170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety.
    Clothier HJ; Shetty AN; Mesfin Y; Mackie M; Pearce C; Buttery JP
    Vaccine; 2024 Feb; 42(5):1108-1115. PubMed ID: 38262811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In brief: Guillain-Barré syndrome with the Johnson and Johnson COVID-19 vaccine.
    Med Lett Drugs Ther; 2021 Aug; 63(1630):121. PubMed ID: 34550109
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guillain-Barré Syndrome Associated with COVID-19 Vaccination.
    Finsterer J; Scorza FA; Scorza CA
    Emerg Infect Dis; 2022 May; 28(5):1079-1080. PubMed ID: 35447058
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guillain-Barré Syndrome and COVID-19 Vaccine: A Multicenter Retrospective Study of 46 Cases.
    Castiglione JI; Crespo JM; Bendersky M; Silveira FO; Lecchini L; Luis MB; Zambrano FC; Cotti N; Simison CJ; Aguirre F; Piedrabuena MA; Alonso RN; Azcona CL; Sosa PS; Maldonado E; Varela F; Bettini M; Rey RD; Cejas LL; Rugiero M; Reisin R; Barroso F
    J Clin Neuromuscul Dis; 2023 Sep; 25(1):1-10. PubMed ID: 37611264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States.
    Wallace M; Rosenblum HG; Moulia DL; Broder KR; Shimabukuro TT; Taylor CA; Havers FP; Meyer SA; Dooling K; Oliver SE; Hadler SC; Gargano JW
    Vaccine; 2023 Oct; 41(44):6456-6467. PubMed ID: 37527956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review.
    Shafiq A; Salameh MA; Laswi I; Mohammed I; Mhaimeed O; Mhaimeed N; Mhaimeed N; Paul P; Mushannen M; Elshafeey A; Fares A; Holroyd S; Zakaria D
    J Clin Pharmacol; 2022 Mar; 62(3):291-303. PubMed ID: 34921562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guillain-Barre syndrome following COVID-19 vaccines: A scoping review.
    Lahoz Fernandez PE; Miranda Pereira J; Fonseca Risso I; Baleeiro Rodrigues Silva P; Freitas Barboza IC; Vieira Silveira CG; Diogo Silva G; Marzorati Kuntz Puglia P; Genaro Mutarelli E
    Acta Neurol Scand; 2022 Apr; 145(4):393-398. PubMed ID: 34967005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.